Frequently Asked Questions

Raysun supports project-specific development and manufacturing programs involving peptide APIs, oligonucleotides, growth hormone products and sterile drug products. The final scope may include process, analytical, quality, regulatory, technology-transfer and manufacturing activities, subject to technical review and written agreement.

Programs may be reviewed from early technical assessment and process development through scale-up, GMP transfer, clinical supply and commercial-readiness planning. The services offered for an individual program depend on its modality, development stage, available data and intended markets.

Raysun can evaluate generic and proprietary development opportunities. Confidential sequences, structures and project information can be discussed under an appropriate confidentiality agreement before detailed technical review.

Share the product type, sequence or structure when available, target quality attributes, required scale, development phase, intended market and expected timeline. Our team will review the information and identify the next technical and commercial steps.

Regulatory strategy, CMC content planning, document coordination and submission-readiness support may be incorporated into an agreed program. All deliverables are based on verified project and facility evidence; no filing or authority approval is implied.

Project-based and longer-term collaboration structures can be considered after the required technical scope, team resources, governance and deliverables have been defined.

The appropriate synthetic route is selected according to sequence length, modification pattern, impurity profile, scale and intended use. A program may use solid-phase, solution-phase or hybrid approaches, followed by purification, isolation and analytical characterization.

Research-grade material is intended for non-clinical laboratory work under an agreed specification. GMP material is produced under an approved quality system with defined controls, documentation, traceability, release testing and change management appropriate to its intended regulated use.

The analytical control strategy is defined for each product and may include identity, purity, related substances, water, residual solvents, counter-ion, microbial and other product-specific tests. Methods and acceptance criteria are confirmed during project review.

Feasible scale is evaluated case by case using the sequence, process performance, equipment fit, quality requirements and supply plan. Batch size and scale-up strategy are confirmed only after technical assessment.

Programs involving selected terminal modifications, side-chain modifications, lipidation, PEG-related chemistry or other conjugation strategies may be reviewed for technical feasibility, analytical requirements and manufacturing fit.

No. Raysun works with qualified pharmaceutical, biotechnology and research organizations through appropriate scientific, quality and regulatory pathways. Materials are not supplied or represented as finished products for unapproved human use.

Solvent selection should consider sequence charge, hydrophobicity, concentration, pH and downstream use. Begin with a small test portion whenever possible and avoid repeated pH adjustment or prolonged exposure to conditions that may affect stability.

Free cysteine residues may oxidize or form intermolecular species. Minimize unnecessary exposure to air, select compatible buffers and handling conditions, and define suitable controls when reduced material must be maintained.

Sequence-based assessment can identify likely solubility risks, but actual behavior depends on concentration, pH, ionic strength, counter-ion and formulation conditions. Small-scale experimental confirmation is recommended.

Storage conditions must follow the product-specific label, certificate and approved stability information. In general, control temperature, moisture and light exposure, and avoid unnecessary freeze-thaw cycles or repeated container opening.

Potential pathways include oxidation, deamidation, hydrolysis, isomerization, aggregation and other sequence-dependent changes. A suitable stability-indicating analytical strategy is used to evaluate relevant risks for each product.

Oligonucleotide programs are typically based on controlled solid-phase synthesis followed by cleavage, deprotection, purification, isolation and analytical characterization. The precise process depends on sequence, backbone chemistry, modifications and scale.

Raysun can assess selected antisense, siRNA and other synthetic oligonucleotide programs, including projects that require specialized modifications or conjugation. Feasibility is confirmed from the complete technical requirements.

Backbone, sugar, terminal and conjugation modifications may be considered according to the sequence and intended use. Chemistry availability, raw-material strategy, impurity risks and analytical coverage are evaluated before acceptance.

A product-specific control strategy may cover identity, assay, purity, sequence-related impurities, residual solvents, counter-ions, water and microbiological attributes. Final methods and specifications are established for the agreed development stage.

Provide the sequence, backbone and sugar chemistry, terminal modifications, conjugates, target scale, required quality grade, analytical expectations, intended use, target market and desired timeline when available.